药学学报, 2021, 56(5): 1400-1408
引用本文:
王琨, 颜海燕, 吴硕, 王辉强, 李玉环, 蒋建东. 清肺排毒汤的体外抗冠状病毒作用研究[J]. 药学学报, 2021, 56(5): 1400-1408.
WANG Kun, YAN Hai-yan, WU Shuo, WANG Hui-qiang, LI Yu-huan, JIANG Jian-dong. Inhibitory effect of Qing-Fei-Pai-Du decoction on coronavirus in vitro[J]. Acta Pharmaceutica Sinica, 2021, 56(5): 1400-1408.

清肺排毒汤的体外抗冠状病毒作用研究
王琨1,2, 颜海燕1,2, 吴硕1,2, 王辉强1,2, 李玉环1,2*, 蒋建东2*
1. 中国医学科学院、北京协和医学院医药生物技术研究所, 中国医学科学院抗病毒药物研究重点实验室, 北京 100050;
2. 中国医学科学院、北京协和医学院医药生物技术研究所, 抗感染药物研究北京市重点实验室, 北京 100050
摘要:
清肺排毒汤由中医经典方剂组合而成,在新冠肺炎的治疗中发挥了重要作用。本研究主要考察了清肺排毒汤(Qing-Fei-Pai-Du decoction,QFPDD)对冠状病毒的抑制作用及其作用机制。本研究采用PrestoBlue细胞活性检测试剂检测QFPDD的细胞毒性;实时荧光定量PCR法(quantitive reverse transcription PCR,qRT-PCR)和免疫荧光法(immunofluorescence assay,IF)检测QFPDD在RNA和蛋白水平对冠状病毒的抑制作用;qRT-PCR检测QFPDD对冠状病毒吸附和穿入的作用;qRT-PCR检测QFPDD对干扰素(interferon,IFN)以及干扰素刺激基因(interferon stimulated genes,ISGs)的作用。本课题研究结果表明,在RNA和蛋白水平,QFPDD在无毒浓度下可剂量依赖性地抑制冠状病毒复制,时间进程分析发现,QFPDD主要在冠状病毒感染的早期阶段发挥作用。此外,初步机制研究表明,QFPDD一方面可以通过抑制病毒的吸附阻碍其入胞过程,另一方面QFPDD也通过上调IFN和ISGs的表达发挥抗病毒作用。本研究为QFPDD的临床应用提供了理论基础。
关键词:    冠状病毒      清肺排毒汤      干扰素      入胞      作用机制     
Inhibitory effect of Qing-Fei-Pai-Du decoction on coronavirus in vitro
WANG Kun1,2, YAN Hai-yan1,2, WU Shuo1,2, WANG Hui-qiang1,2, LI Yu-huan1,2*, JIANG Jian-dong2*
1. CAMS Key Laboratory of Antiviral Drug Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China;
2. Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
Abstract:
Qing-Fei-Pai-Du decoction (QFPDD) is a combination of traditional Chinese medicine and plays an important role in the treatment of coronavirus disease 2019 (COVID-19). This study investigated the inhibitory effect of QFPDD on coronavirus replication and antiviral mechanism. The cytotoxicity of QFPDD was determined by PrestoBlue cell viability assay. Quantitive reverse transcription PCR (qRT-PCR) and immunofluorescence assay (IF) were used to detect the inhibitory effects of QFPDD on coronavirus at RNA and protein levels. qRT-PCR was used to detect the adsorption and penetration of coronavirus after QFPDD treatment. The effects of QFPDD on interferon (IFN) and interferon-stimulated genes (ISGs) were also detected by qRT-PCR. The results showed that QFPDD inhibited coronavirus at RNA and protein levels in a dose-dependent manner at non-toxic concentration, and QFPDD targeted in the early stages of coronavirus infection cycle. Preliminary mechanism studies have shown that QFPDD can directly block the virus entry into the cell by inhibiting virus adsorption, and QFPDD can also play an antiviral role by up-regulating the expression of IFN and ISGs. These results indicate QFPDD as a drug potential to treat coronavirus infection.
Key words:    coronavirus    Qing-Fei-Pai-Du decoction    interferon    entry    mechanism   
收稿日期: 2020-12-08
DOI: 10.16438/j.0513-4870.2020-1879
基金项目: 国家重点研发计划项目(2020YFC0845400);新冠应急防控-基科费(2020HY320001).
通讯作者: 李玉环,Tel:86-10-63010984,Fax:86-10-63017302,E-mail:yuhuanlibj@126.com;蒋建东,Tel:86-10-63188423,Fax:86-10-63017302,E-mail:jiang.jdong@163.com
Email: yuhuanlibj@126.com;jiang.jdong@163.com
相关功能
PDF(1600KB) Free
打印本文
0
作者相关文章
王琨  在本刊中的所有文章
颜海燕  在本刊中的所有文章
吴硕  在本刊中的所有文章
王辉强  在本刊中的所有文章
李玉环  在本刊中的所有文章
蒋建东  在本刊中的所有文章

参考文献:
[1] Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses[J]. Nat Rev Microbiol, 2019, 17:181-192.
[2] Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus:classifying 2019-nCoV and naming it SARS-CoV-2[J]. Nat Microbiol, 2020, 5:536-544.
[3] Shereen MA, Khan S, Kazmi A, et al. COVID-19 infection:origin, transmission, and characteristics of human coronaviruses[J]. J Adv Res, 2020, 24:91-98.
[4] Yang L, Wang HQ, Li YH. Research progress on therapeutic drugs for corona virus disease 2019[J]. Acta Pharm Sin (药学学报), 2020, 55:1081-1090.
[5] He QH, Liu YK, Sun XR, et al. Chinese medicine to novel coronavirus pneumonia sword--the meaning and role of Qing-Fei-Pai-Du decoction issued by the State Administration of traditional Chinese Medicine[J/OL]. J Tradit Chin Med (中医杂志), 2020. http://kns.cnki.net/kcms/detail/11.2166.R.20200224.1038. 008.html.
[6] Mao J, Lu TL. Discussion on COVID-19 treated by Qing Fei Pai Du Tang from theory of traditional Chinese medicine[J]. J Pract Tradit Chin Int Med (实用中医内科杂志), 2020, 34:1-4.
[7] Yang R, Liu H, Bai C, et al. Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019(COVID-19):in silico and experimental study[J]. Pharmacol Res, 2020, 157:104820.
[8] National Health Commission. Novel coronavirus pneumonia diagnosis and treatment plan (Trial Version 7) (新型冠状病毒肺炎诊疗方案(试行第七版))[S/OL]. 2020-3-3. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
[9] Xin S, Cheng X, Zhu B, et al. Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment[J]. Biomed Pharmacother, 2020, 129:110500.
[10] Lu ZZ, Lu XS. Qingfei Paidu decoction demonstrates the anti-epidemic effects and self-confidence of traditional Chinese medicine[J]. J Tradit Chin Med (中医杂志), 2020, 61:833-834.
[11] Wu H, Wang JQ, Yang YW, et al. Preliminary exploration of the mechanism of Qingfei Paidu decoction against novel coronavirus pneumonia based on network pharmacology and molecular docking technology[J]. Acta Pharm Sin (药学学报), 2020, 55:374-383.
[12] Zhao J, Tian SS, Yang J, et al. Investigating mechanism of Qing-Fei-Pai-Du-Tang for treatment of COVID-19 by network pharmacology[J]. Chin Tradit Herb Drugs (中草药), 2020, 51:829-835.
[13] Abd El-Aziz TM, Stockand JD. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2)-an update on the status[J]. Infect Genet Evol, 2020, 83:104327.
[14] Zhang C, Chen SB, Zhang J, et al. Analysis of chemical drugs applied for clinical trial for the treatment of COVID-19[J]. Acta Pharm Sin (药学学报), 2020, 55:355-365.
[15] Wang HR, Wang X. Advances in research of novel coronavirus related drugs and biological products[J]. Acta Pharm Sin (药学学报), 2020, 55:349-354.
[16] Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19:a randomised, double-blind, placebo-controlled, multicentre trial[J]. Lancet, 2020, 395:1569-1578.
[17] Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19-final report[J]. N Engl J Med, 2020, 383:1813-1826.
[18] Yang Y, Islam MS, Wang J, et al. Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2):a review and perspective[J]. Int J Biol Sci, 2020, 16:1708-1717.
[19] Fan YP, Wang YP, Zhang HM, et al. Analysis on the treatment of new coronavirus pneumonia (COVID-19) from the cold epidemic treatment[J]. J Tradit Chin Med (中医杂志), 2020, 61:369-374.
[20] Tong XL, Li XY, Zhao LH, et al. Discussion on traditional Chinese medicine prevention and treatment strategies of coronavirus disease 2019(COVID-19) from the perspective of "cold-dampness pestilence"[J]. J Tradit Chin Med (中医杂志), 2020, 61:465-470, 553.
[21] Schoggins JW, Wilson SJ, Panis M, et al. A diverse range of gene products are effectors of the type I interferon antiviral response[J]. Nature, 2011, 472:481-485.
[22] Ivashkiv LB, Donlin LT. Regulation of type I interferon responses[J]. Nat Rev Immunol, 2014, 14:36-49.
[23] Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes:a complex web of host defenses[J]. Annu Rev Immunol, 2014, 32:513-545
相关文献:
1.吴昊, 王佳琪, 杨雨薇, 李天怡, 曹一佳, 曲玉霞, 靳玉洁, 张晨宁, 孙毅坤.基于网络药理学和分子对接技术初步探索“清肺排毒汤”抗新型冠状病毒肺炎作用机制[J]. 药学学报, 2020,55(3): 374-383
2.杨璐, 王辉强, 李玉环.COVID-19治疗药物的研究进展[J]. 药学学报, 2020,55(6): 1081-1090